Antibody against human prostaglandin E2 receptor EP4
AssigneeNb Health Laboratory Co., Ltd.
InventorsKiyoshi Takayama, Tomoko Shimizu, Yuji Urushibata, Yukihiko Sugimoto
Life of this patent
Estimating the term…
Abstract
It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.
Claims9
A monoclonal antibody or an antigen-binding fragment thereof, comprising:
- heavy chain CDR1 comprising the amino acid sequence shown in SEQ ID NO:
- 45, heavy chain CDR2 comprising the amino acid sequence shown in SEQ ID NO:
- 46, heavy chain CDR3 comprising the amino acid sequence shown in SEQ ID NO:
- 47, light chain CDR1 comprising the amino acid sequence shown in SEQ ID NO:
- 48, light chain CDR2 comprising the amino acid sequence shown in SEQ ID NO:
- 49, and light chain CDR3 comprising the amino acid sequence shown in SEQ ID NO:
- 50;
- wherein the antibody or antigen-binding fragment specifically binds to the extracellular domain of EP4, inhibits the function of EP4, and binds to neither EP1, EP2 nor EP3.
Dependencies are inferred from the claim text.